NEW YORK (GenomeWeb) – Transposagen announced today that it has licensed CRISPR/Cas9 intellectual property from the Broad Institute.

With the non-exclusive license agreement, Transposagen will be able to combine CRISPR/Cas9 genome editing technology with its Footprint-Free Gene Editing System. The combination allows for "precision gene editing without fear of undesired off-target effects," Transposagen CEO John Printen said in a statement.

To read the full story....

Register for Free.

...and receive Daily News bulletins.

Already have an account?
Login Now.

A new report highlights the potential threats posed by advances in synthetic biology, NPR reports.

A Bloomberg reporter tried to get her genetic data deleted, but found it's not so simple to do.

Johns Hopkins University's Steven Salzberg and his colleagues have come up with a new estimate for the number of human genes, Nature News reports.

In Genome Research this week: study of intra-tumor heterogeneity, workflow resources for EPIGEN-Brazil, and more.